ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Completed · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.

Key facts

Study ID

NCT00051493

Run by

Eli Lilly and Company

People needed

50

Starts

2002-04-01

Expected to finish

2002-12-01

Last updated by the study team

2006-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You have a diagnosis of non-small cell lung cancer.
• You have received no prior chemotherapy.
• You have at least one measurable lesion.
• You have an adequate performance status.
• You are at least 18 years of age.

You may not qualify if…

• You have previously received chemotherapy for your lung cancer.
• You have received radiation within the last 30 days.
• You have active infection or other serious condition.
• You have brain metastasis.
• You have recently lost a significant amount of weight.

Where it is running

• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.